SRRK vs KYMR vs ARQT vs IMVT vs ACVA

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Scholar Rock Holding Corporation (SRRK) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -80. 4% for ACV Auctions Inc. (ACVA). Over 10 years, the gap is even starker: SRRK returned +199. 7% versus ACVA's -79. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 1. 15β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 29% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 44% for Scholar Rock Holding Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Scholar Rock Holding Corporation (SRRK) is the more profitable company, earning 0.

0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRRK leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACV Auctions Inc.

(ACVA) trades at 33. 6x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 44. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 71. 8% to $35. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Both have compounded well over 10 years (KYMR: +154. 4%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SRRK (Healthcare) and KYMR (Healthcare) and ARQT (Healthcare) and IMVT (Healthcare) and ACVA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SRRK is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; ACVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.